Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4846 AL 4860

No Effect of Omega-3 Fatty Acid Supplementation on Cognition and Mood in Individuals with Cognitive Impairment and Probable Alzheimer's Disease: A Randomised Controlled Trial

Phillips MA, Childs CE, Calder PC, Rogers PJ.

Int J Mol Sci. 2015 Oct 16;16(10):24600-13. doi: 10.3390/ijms161024600.

Benefits and risks of add-on therapies for Alzheimer's disease

Magierski R, Sobow T.

Neurodegener Dis Manag. 2015 Oct;5(5):445-62. doi: 10.2217/nmt.15.39. Epub 2015 Oct 30.

Memantine ER/Donepezil: A Review in Alzheimer's Disease

Greig SL.

CNS Drugs. 2015 Nov;29(11):963-70. doi: 10.1007/s40263-015-0287-2.

Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer's disease

Venigalla M, Sonego S, Gyengesi E, Sharman MJ, Münch G.

Neurochem Int. 2016 May;95:63-74. doi: 10.1016/j.neuint.2015.10.011. Epub 2015 Oct 31.

Amyloid Fibres: Inert End-Stage Aggregates or Key Players in Disease?

Tipping KW, van Oosten-Hawle P, Hewitt EW, Radford SE.

Trends Biochem Sci. 2015 Dec;40(12):719-727. doi: 10.1016/j.tibs.2015.10.002. Epub 2015 Nov 2.

The Role of Oxidative Stress-Induced Epigenetic Alterations in Amyloid-β Production in Alzheimer's Disease

Zuo L, Hemmelgarn BT, Chuang CC, Best TM.

Oxid Med Cell Longev. 2015;2015:604658. doi: 10.1155/2015/604658. Epub 2015 Oct 12.

Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease

Wicke K, Haupt A, Bespalov A.

Expert Opin Investig Drugs. 2015;24(12):1515-28. doi: 10.1517/13543784.2015.1102884. Epub 2015 Nov 7.

Defining the Genetic Architecture of Alzheimer's Disease: Where Next

Sims R, Williams J.

Neurodegener Dis. 2016;16(1-2):6-11. doi: 10.1159/000440841. Epub 2015 Nov 10.

Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease

Maqbool M, Mobashir M, Hoda N.

Eur J Med Chem. 2016 Jan 1;107:63-81. doi: 10.1016/j.ejmech.2015.10.018. Epub 2015 Oct 21.

Management of LUTS in patients with dementia and associated disorders 

Averbeck MA, Altaweel W, Manu-Marin A, Madersbacher H.

Neurourol Urodyn. 2017 Feb;36(2):245-252. doi: 10.1002/nau.22928. Epub 2015 Nov 20.

Basic aspects in selecting a suitable transgenic rodent model for Alzheimer's disease

Balmus IM, Ciobica A, Negura A, Negura L, Anton E.

Psychiatr Danub. 2015 Dec;27(4):338-45.

Current and Future Treatments for Alzheimer Disease

Small GW, Greenfield S.

Am J Geriatr Psychiatry. 2015 Nov;23(11):1101-5. doi: 10.1016/j.jagp.2015.08.006. Epub 2015 Sep 9.

Real-world evaluation of compliance and preference in Alzheimer's disease treatment

Pai MC, Aref H, Bassil N, Kandiah N, Lee JH, Srinivasan AV, diTommaso S, Yuksel O.

Clin Interv Aging. 2015 Nov 3;10:1779-87. doi: 10.2147/CIA.S85319. eCollection 2015.

Comparative study of the neuroprotective and nootropic activities of the carboxylate and amide forms of the HLDF-6 peptide in animal models of Alzheimer's disease

Bogachouk AP, Storozheva ZI, Solovjeva OA, Sherstnev VV, Zolotarev YA, Azev VN, Rodionov IL, Surina EA, Lipkin VM.

J Psychopharmacol. 2016 Jan;30(1):78-92. doi: 10.1177/0269881115616393. Epub 2015 Dec 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias